IP Library Granted Patent US 8,816,058
Granted Patent B2
US 8,816,058 · App. 13/517,807 · Granted Aug 26, 2014

Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,816,058
App. No.
13/517,807
Granted
Aug 26, 2014
Kind
B2
Abstract

Isolated polynucleotides are provided which encode antibody VH and VL polypeptides, and anti-CD100 antibodies and antigen-binding fragments thereof. In another aspect, the invention provides a vector comprising a polynucleotide of the invention. In another aspect, the invention provides a host cell comprising the vector of the invention. In another aspect, the invention provides a method of producing an antibody of the invention, e.g., for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers.

Claims (24)

1. An isolated polynucleotide comprising a nucleotide sequence which encodes an antibody heavy chain variable region (VH) polypeptide comprising the amino acid sequence SEQ ID NO: 9; wherein an antibody comprising said VH polypeptide and a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences consisting of SEQ ID NOs: 14, 15, and 16, respectively, can specifically bind to CD100.

2. The polynucleotide of claim 1 , wherein the nucleotide sequence encoding said VH polypeptide is optimized for increased expression without changing the amino acid sequence of said VH polypeptide.

3. The polynucleotide of claim 2 , wherein said optimization comprises identification and removal of splice donor and splice acceptor sites.

4. The polynucleotide claim 2 , wherein said optimization comprises optimization of codon usage for the cells expressing said polynucleotide.

5. The polynucleotide of claim 1 , wherein the nucleotide sequence comprises SEQ ID NO: 19.

6. The polynucleotide of claim 5 , wherein said nucleotide sequence consists of SEQ ID NO: 19.

7. An isolated polynucleotide comprising a nucleotide sequence which encodes an antibody light chain variable region (VL) polypeptide comprising the amino acid sequence SEQ ID NO: 17; wherein an antibody comprising said VL polypeptide and a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences consisting of SEQ ID NOs: 6, 7, and 8, respectively, can specifically bind to CD100.

8. The polynucleotide of claim 7 , wherein the nucleotide sequence encoding said VL polypeptide is optimized for increased expression without changing the amino acid sequence of said VL polypeptide.

9. The polynucleotide of claim 8 , wherein said optimization comprises identification and removal of splice donor and splice acceptor sites.

10. The polynucleotide of claim 8 , wherein said optimization comprises optimization of codon usage for the cells expressing said polynucleotide.

11. The polynucleotide of claim 7 , wherein the nucleotide sequence comprises SEQ ID NO: 21.

12. The polynucleotide of any claim 11 , wherein said nucleotide sequence consists of SEQ ID NO: 21.

13. A composition comprising an isolated VH encoding polynucleotide and an isolated VL encoding polynucleotide, wherein said VH encoding polynucleotide comprises a cDNA that encodes a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences consisting of SEQ ID NOs: 6, 7, and 8, respectively; wherein said VL encoding polynucleotide comprises a cDNA that encodes a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences consisting of SEQ ID NOs: 14, 15, and 16, respectively; and wherein an antibody or fragment thereof encoded by said VH and VL encoding polynucleotides specifically binds CD100.

14. The composition of claim 13 wherein said VH encoding polynucleotide and said VL encoding polynucleotide are contained on a single vector or on separate vectors.

15. A host cell comprising the composition of claim 14 .

16. A method of producing an antibody or fragment thereof which specifically binds CD100, comprising culturing the host cell of claim 15 and recovering said antibody or fragment thereof.

17. A vector comprising the polynucleotide of claim 1 .

18. A host cell comprising the vector of claim 17 .

19. A vector comprising the polynucleotide of claim 7 .

20. A host cell comprising the vector of claim 19 .

21. A recombinant host cell comprising a VH-encoding polynucleotide and a VL-encoding polynucleotide, wherein the VH-encoding polynucleotide encodes a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences consisting of SEQ ID NOs: 6, 7, and 8, respectively, wherein the VL-encoding polynucleotide encodes a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences consisting of SEQ ID NOs: 14, 15, and 16, respectively, wherein the VH encoding polynucleotide and the VL encoding polynucleotide are situated on separate vectors, and wherein an antibody or fragment thereof encoded by the VH and VL encoding polynucleotides specifically binds CD100.

22. The host cell of claim 21 , wherein the VH polypeptide comprises the amino acid sequence SEQ ID NO:9 and the VL polypeptide comprises the amino acid sequence SEQ ID NO:17.

23. The host cell of claim 22 , which produced from the CHO cell line.

24. A method of producing an antibody or fragment thereof which specifically binds CD100, comprising culturing the host cell of claim 22 and recovering the antibody or fragment thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 9, 2023
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 062308/0405 →
SECURITY INTEREST Recorded Aug 10, 2020
From: VACCINEX, INC.
To: 3I, L.P.
Reel/Frame 053440/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2012
From: SMITH, ERNEST S.; FISHER, TERRENCE LEE
To: VACCINEX, INC.
Reel/Frame 028378/0159 →